Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Shares Sold by Vivo Capital LLC

Vivo Capital LLC lowered its holdings in Alpine Immune Sciences, Inc. (NASDAQ:ALPN) by 10.5% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 819,275 shares of the biotechnology company’s stock after selling 95,638 shares during the period. Alpine Immune Sciences comprises about 1.3% of Vivo Capital LLC’s investment portfolio, making the stock its 14th biggest holding. Vivo Capital LLC owned about 1.41% of Alpine Immune Sciences worth $15,615,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently bought and sold shares of the business. Allspring Global Investments Holdings LLC increased its stake in shares of Alpine Immune Sciences by 745.5% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 1,488 shares of the biotechnology company’s stock valued at $28,000 after acquiring an additional 1,312 shares during the period. AJOVista LLC acquired a new stake in shares of Alpine Immune Sciences in the 4th quarter valued at $64,000. China Universal Asset Management Co. Ltd. lifted its position in Alpine Immune Sciences by 429.8% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 6,723 shares of the biotechnology company’s stock worth $128,000 after acquiring an additional 5,454 shares during the last quarter. Barclays PLC increased its holdings in shares of Alpine Immune Sciences by 44.3% during the 3rd quarter. Barclays PLC now owns 9,126 shares of the biotechnology company’s stock worth $104,000 after purchasing an additional 2,801 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank bought a new position in Alpine Immune Sciences during the fourth quarter valued at about $182,000. Institutional investors own 75.17% of the company’s stock.

Alpine Immune Sciences Trading Up 0.1 %

Shares of NASDAQ ALPN traded up $0.05 during midday trading on Thursday, hitting $64.75. The company’s stock had a trading volume of 101,231 shares, compared to its average volume of 1,884,510. The stock has a fifty day moving average price of $48.61 and a 200 day moving average price of $29.78. Alpine Immune Sciences, Inc. has a one year low of $7.55 and a one year high of $64.75. The firm has a market capitalization of $4.25 billion, a price-to-earnings ratio of -101.09 and a beta of 0.97.

Alpine Immune Sciences (NASDAQ:ALPN) last posted its quarterly earnings results on Monday, March 18th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.32) by $0.47. Alpine Immune Sciences had a negative net margin of 54.66% and a negative return on equity of 15.54%. The company had revenue of $30.85 million for the quarter, compared to analyst estimates of $6.90 million. On average, equities research analysts predict that Alpine Immune Sciences, Inc. will post -1.74 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on ALPN shares. TD Cowen reissued a “hold” rating on shares of Alpine Immune Sciences in a report on Tuesday, April 16th. Guggenheim assumed coverage on shares of Alpine Immune Sciences in a research note on Tuesday, April 9th. They set a “buy” rating and a $55.00 price objective for the company. Morgan Stanley reiterated an “equal weight” rating and issued a $65.00 target price (up from $47.00) on shares of Alpine Immune Sciences in a research note on Thursday, April 11th. SVB Leerink downgraded shares of Alpine Immune Sciences from an “outperform” rating to a “market perform” rating and raised their target price for the company from $42.00 to $65.00 in a research note on Friday, April 12th. Finally, Royal Bank of Canada reissued a “sector perform” rating and issued a $65.00 price target (up from $41.00) on shares of Alpine Immune Sciences in a report on Thursday, April 11th. Eight analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Alpine Immune Sciences presently has an average rating of “Hold” and a consensus target price of $50.33.

Alpine Immune Sciences Company Profile

Alpine Immune Sciences, Inc operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of immunotherapies through protein engineering technologies for treating autoimmune and inflammatory diseases. The company's product pipeline includes Povetacicept, a dual B cell cytokine antagonist, which is in Phase 2 clinical trial for the treatment of multiple autoimmune and inflammatory diseases; and Acazicolcept, a dual inhibitor of the CD28 and ICOS T cell costimulatory pathways that is in preclinical trial for the treatment of systemic lupus erythematosus.